Gulf International Bank UK Ltd Cuts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Gulf International Bank UK Ltd lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,492 shares of the company’s stock after selling 71 shares during the quarter. Gulf International Bank UK Ltd’s holdings in IDEXX Laboratories were worth $2,684,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of IDXX. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories in the third quarter worth about $25,000. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories in the fourth quarter worth about $31,000. Ashton Thomas Securities LLC purchased a new stake in IDEXX Laboratories in the third quarter worth about $37,000. Kestra Investment Management LLC purchased a new stake in IDEXX Laboratories in the fourth quarter worth about $38,000. Finally, Crews Bank & Trust purchased a new stake in IDEXX Laboratories in the fourth quarter worth about $41,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Down 0.9 %

Shares of IDEXX Laboratories stock opened at $437.11 on Friday. The company has a market cap of $35.55 billion, a price-to-earnings ratio of 40.97, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The company’s 50 day moving average is $435.31 and its 200 day moving average is $451.54. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $583.39. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

Insider Activity at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This trade represents a 49.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

IDXX has been the topic of a number of recent analyst reports. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday. Morgan Stanley cut their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price target on the stock. Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a report on Monday, February 10th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.